Scramble for Sarcoma 2024

Middle Finger To Cancer (“MF2C”) stands with patients seeking treatment for sarcomas of the limb, providing benevolent assistance to lessen their burden and help them fight their battle. Additionally, MF2C encourages the pursuit of alternative medical opinions and treatments in order to defeat sarcomas of the limb.

Why the Middle Finger? Click here to read our story!

MF2C has partnered with Memorial Sloan Kettering Cancer Center (“MSKCC”) to provide financial assistance for costly medical bills and travel expenses for patients seeking top rated specialist care. Our assistance includes regular coordination with MSKCC medical staff to fund limb saving and lifesaving treatments not provided in the United States.

Tumor Necrosis Factor-Alpha in Isolated Limb Profusion has been successfully utilized in Europe for twenty-plus years to treat limb sarcomas. As part of its mission, Middle Finger To Cancer actively encourages the drug manufacturers to submit the treatment to the Food and Drug Administration (FDA) for approval in the United States.